TLX News

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

Investor Education Webinar

Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging

Telix to Participate in Oppenheimer and TD Cowen Conferences

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

Telix Full Year Results 2025 Investor Webcast Notification

PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch